Molecular marker for recurrent spontaneous abortion and diagnostic use

By detecting the expression level of JAZF1 gene, the problem of diagnosis and prevention of recurrent miscarriage was solved. It was found that JAZF1, as a diagnostic marker, contributes to clinical application, promotes the survival and decidualization of endometrial stromal cells, and solves recurrent Diagnosis and prevention problems of miscarriage.

WO2024230481A1PCT designated stage expired Publication Date: 2024-11-14THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY (GUANGZHOU SEVERE MATERNAL TREATMENT CENTER GUANGZHOU ROUJI HOSPITAL)
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/089478
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-04-24
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The pathogenesis of recurrent miscarriage is still unclear, the existing technology is difficult to effectively diagnose and prevent, and there is a lack of effective molecular markers and treatment strategies.

Method used

By detecting the expression level of JAZF1 gene in decidual tissue and intimal cells, using qRT-PCR, Western blot, immunohistochemistry and other methods, JAZF1 gene detection reagents and diagnostic products are provided to assist in the diagnosis of recurrent miscarriage and prevention.

Benefits of technology

It was found that the expression of JAZF1 is closely related to recurrent miscarriage. As a potential diagnostic marker, JAZF1 helps clinically diagnose and prevent recurrent miscarriage, and promotes the survival of endometrial stromal cells and normal decidualization, and maintains normal pregnancy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024089478_14112024_PF_FP_ABST
    Figure CN2024089478_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are a molecular marker for recurrent spontaneous abortion and a diagnostic use thereof, relating to the technical field of biomedicine. Also provided is a use of a JAZF1 gene in preparation of a product for abortion diagnosis or assisted diagnosis. It is found for the first time that the expression level of JAZF1 is closely related to the recurrent spontaneous abortion, specifically, the expression of JAZF1 in decidua tissues and endometrial tissues of a recurrent spontaneous abortion patient is downregulated, indicating the potential possibility that JAZF1 serves as a diagnostic marker for recurrent spontaneous abortion, and is conducive to clinical diagnosis and prevention of recurrent spontaneous abortion. It is proposed for the first time that JAZF1 can promote the survival of endometrial stromal cells and normal decidualization, thereby maintaining normal pregnancy.
Need to check novelty before this filing date? Find Prior Art

Description

Molecular markers and diagnostic applications of recurrent spontaneous abortion Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to a molecular marker for recurrent spontaneous abortion and its diagnostic application. Background Art

[0002] Recurrent spontaneous abortion (RSA), also known as recurrent pregnancy loss (RPL), is a highly heterogeneous condition defined as two or more spontaneous miscarriages, including consecutive biochemical pregnancies (documented by ultrasound or histopathology). In addition to chromosomal abnormalities, immune system abnormalities, and uterine malformations, endometrial dysfunction is also considered an important cause of RSA. Furthermore, recurrent miscarriage increases the incidence of adverse pregnancy outcomes in subsequent pregnancies, such as preterm birth, premature rupture of membranes, and low birth weight.

[0003] Decidualization of the endometrium is crucial for the establishment and maintenance of pregnancy. During this period, decidualization of endometrial stromal cells (EnSCs) involves a multistep reprogramming process in which EnSCs transform into secretory decidual stromal cells (DSCs), with the secretion of prolactin (PRL) and insulin-like growth factor binding protein-1 (IGFBP-1) serving as the classic hallmarks of decidualization. Decidualization not only limits excessive trophoblast infiltration but also directly or indirectly influences immune cell recruitment, distribution, and function, spiral artery remodeling, and placenta formation through the secretion of growth factors and cytokines. Defects in decidualization can lead to a variety of pregnancy complications, including RSA, recurrent implantation failure (RIF), and preeclampsia. However, the pathogenesis of endometrial dysfunction in RSA remains unclear.

[0004] Numerous studies have found excessive apoptosis in DSCs of patients with early miscarriage and recurrent miscarriage. Prior art studies have shown that acrylamide (ACR) inhibits cyclin D3 and p21 while upregulating apoptosis-related molecules BAX and cleaved-caspase 3, thereby impairing decidualization and causing a reduction in the number of mouse embryos (Yu D., Liu Q., Qiao B., et al. Exposure to acrylamide inhibits uterine decidualization via suppression of cyclin D3 / p21 and apoptosis in mice. J Hazard Mater 388:121785, 2020.). Other studies have found that abnormally increased BAX levels can damage stromal cell decidualization by inducing cell apoptosis, leading to recurrent miscarriage (Al-Rubaye S., Ghaderian SMH, Salehpour S., et al. Aberrant expression of BAX, MEG3, and miR-214-3P genes in recurrent pregnancy loss. Gynecol Endocrinol 37(7): 660-664, 2021.; Lv X., Cai Z. and Li S. Increased apoptosis rate of human decidual cells and cytotrophoblasts in patients with recurrent spontaneous abortion as a result of abnormal expression of CDKN1A and Bax. Exp Ther Med 12(5): 2865-2868, 2016.).

[0005] Currently, the pathogenesis of recurrent spontaneous abortion is still unclear. Providing a molecular marker for recurrent spontaneous abortion and providing corresponding prevention and treatment strategies have important theoretical and clinical significance.

[0006] Summary of the Invention

[0007] The purpose of the present invention is to provide an application of the JAZF1 gene in the preparation of products for the diagnosis or auxiliary diagnosis of miscarriage, and to provide a reference for the diagnosis and prevention of recurrent miscarriage by detecting the expression level of the JAZF1 gene in the test sample.

[0008] In order to achieve the above-mentioned object of the invention, the technical solution of the present invention is as follows:

[0009] In one aspect, the present invention provides the use of the JAZF1 gene in preparing products for the diagnosis or auxiliary diagnosis of miscarriage.

[0010] Preferably, the miscarriage is recurrent miscarriage.

[0011] Preferably, the diagnostic product comprises a reagent for detecting the expression level of the JAZF1 gene.

[0012] Further preferably, the reagent detects the JAZF1 gene mRNA expression level or protein expression level.

[0013] Preferably, the diagnostic product is selected from one or more of a kit, a gene chip, a protein chip, a preparation, a kit quality control product, and a kit standard product.

[0014] Preferably, the test sample is selected from one or more of decidual tissue, endometrial tissue, and decidual stromal cells.

[0015] More preferably, the test sample is selected from one or more of decidual tissue and decidual stromal cells.

[0016] Preferably, the JAZF1 gene is differentially expressed in samples from patients with recurrent spontaneous abortion.

[0017] Further preferably, the expression of JAZF1 gene in patients with recurrent spontaneous abortion is decreased compared with normal healthy people.

[0018] Preferably, the diagnostic products include: products for diagnosing recurrent miscarriage using qRT-PCR, immunoassay, Western blot assay, immunohistochemistry assay, immunofluorescence, flow cytometry, and single-cell sequencing.

[0019] Further preferably, the product for diagnosing recurrent spontaneous abortion by qRT-PCR comprises at least a pair of primers for specifically amplifying the JAZF1 gene.

[0020] Preferably, the application steps are as follows:

[0021] (1) Detecting the expression level of the JAZF1 gene in the test sample;

[0022] (2) comparing the expression level of the JAZF1 gene in the test sample with that in the control group;

[0023] (3) Compared with the level of the control group, the expression of JAZF1 gene in the test sample is downregulated, indicating that the subject is a miscarriage patient; otherwise, the subject is not a miscarriage patient.

[0024] In another aspect, the present invention provides use of a reagent for detecting the JAZF1 gene in preparing a diagnostic or auxiliary diagnostic product for miscarriage.

[0025] Preferably, the reagent detects the JAZF1 gene mRNA expression level or protein expression level.

[0026] In another aspect, the present invention provides a product for diagnosing or assisting in the diagnosis of miscarriage, wherein the product comprises a reagent for detecting the expression level of the JAZF1 gene in a sample to be tested.

[0027] Preferably, the reagent is selected from a probe set, a primer set or a gene chip.

[0028] Preferably, the product is selected from one or more of a kit, a gene chip, a protein chip, a preparation, a kit quality control product, and a kit standard product.

[0029] In some embodiments of the present invention, the product is a kit, which includes a primer pair for amplifying the JAZF1 gene, a PCR buffer, dNTPs, a reverse transcription system, and an RNA extraction reagent.

[0030] Preferably, the reverse transcription system comprises a reverse transcription reaction solution, a reverse transcriptase and an RNase inhibitor; the RNA extraction reagent comprises Trizol, chloroform, isopropanol and ethanol; the test sample is selected from one or more of decidual tissue, endometrial tissue, and decidual stromal cells; the test sample is selected from one or more of decidual tissue and decidual stromal cells.

[0031] In another aspect, the present invention provides use of a substance that enhances the content or activity of the JAZF1 gene in the preparation of a drug for treating or preventing miscarriage.

[0032] Preferably, the miscarriage is recurrent miscarriage.

[0033] Preferably, the drug further comprises a pharmaceutically acceptable carrier; the pharmaceutically acceptable carrier is selected from one or more of excipients, buffers, emulsifiers, stabilizers, diluents, adhesives, preservatives, and lubricants.

[0034] Further preferably, the pharmaceutical dosage form is selected from one or more of powders, tablets, pills, granules, capsules, solutions, emulsions, suspensions, and oils.

[0035] Preferably, the functions of the application are any one or more of the following: (1) promoting the proliferation of endometrial stromal cells; (2) inhibiting the apoptosis of endometrial stromal cells; (3) maintaining the normal decidualization of endometrial stromal cells.

[0036] The beneficial effects of the present invention are:

[0037] (1) This study first discovered that JAZF1 expression is closely associated with recurrent miscarriage, demonstrating that JAZF1 expression is downregulated in both decidual and endometrial tissues in patients with recurrent miscarriage. This suggests that JAZF1 has the potential to serve as a diagnostic marker for recurrent miscarriage, potentially aiding in the clinical diagnosis and prevention of recurrent miscarriage. (2) This study first proposed that JAZF1 can promote the survival of endometrial stromal cells and normal decidualization, thereby maintaining normal pregnancy. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 (A) is a feature plot showing the mRNA expression level of JAZF1 in DS cells; Figure 1 (B) is a scRNA-seq analysis result of JAZF1 expression in decidual stromal cells from RSA patients (n=6) and normal early pregnancies of matched gestational age (n=5) by using the boxPlot function in the single-cell sequencing R toolkit Seurat.

[0039] Figure 2 shows the expression results of JAZF1 in DS1, DS2 and DS3 analyzed by scRNA-seq.

[0040] Figure 3 (A) shows the expression of JAZF1 in decidual tissue detected by qRT-PCR; Figure 3 (B)-(C) shows the expression of JAZF1 in decidual tissue detected by Western blot.

[0041] Figure 4 (A) shows the expression of JAZF1 in primary decidual stromal cells detected by qRT-PCR; Figure 4 (B)-(C) shows the expression of JAZF1 in primary decidual stromal cells detected by Western blot.

[0042] FIG5 (A) is a diagram showing the expression of JAZF1 in decidual tissue detected by immunohistochemistry; FIG5 (B) is a statistical diagram showing the expression of JAZF1 in decidual tissue detected by immunohistochemistry.

[0043] FIG6 is a diagram showing the expression of JAZF1 in decidual tissue detected by immunofluorescence.

[0044] Figure 7 (A) shows the protein levels of FOXO1, IGFBP1, and JAZF1 in HESCs induced to decidualize detected by Western blot; Figure 7 (B) shows the statistical graph of the protein levels of FOXO1, IGFBP1, and JAZF1 in HESCs induced to decidualize detected by Western blot.

[0045] FIG8 is a graph showing the expression level of JAZF1 in HESCs induced to decidualize detected by immunofluorescence.

[0046] FIG9 is a graph showing the expression levels of JAZF1 in the proliferative and early secretory endometrium of the RSA and normal groups detected by immunohistochemistry.

[0047] Figure 10 (A) shows the expression of JAZF1 in endometrial tissue during the proliferative and mid-secretory phases. The data are from microarray data stored in the Gene Expression Database (GDS2052). Figure 10 (B) shows the expression pattern of JAZF1 analyzed by 10× single-cell transcriptome sequencing (scRNA-seq) of the endometrium at different stages from a public database. The data are from microarray data stored in the Gene Expression Database (GSE111976).

[0048] Figure 11 (A) is a graph showing the expression levels of JAZF1 after siRNA knockdown, knockout, and overexpression treatments detected by qRT-PCR; Figure 11 (B) is a graph showing the expression of JAZF1 after siRNA knockdown, knockout, and overexpression treatments detected by Western blot.

[0049] Figure 12 is a schematic diagram of the structure of the human JAZF1 gene and its CRISPR / Cas9 targeted mutant form (KO).

[0050] FIG13 is a graph showing the expression levels of apoptosis-related genes and decidualization-related genes after knockdown and knockout of JAZF1 detected by qRT-PCR.

[0051] FIG14 shows the expression levels of apoptosis-related genes and decidualization-related genes detected by Western blot after knockdown and knockout of JAZF1.

[0052] FIG15 is a statistical graph showing the expression levels of apoptosis-related genes and decidualization-related genes after knockdown and knockout of JAZF1 detected by Western blot.

[0053] FIG16 is a flow cytometry graph showing the cell apoptosis levels after knockdown, knockout and overexpression of JAZF1.

[0054] Figure 17 (A) is a statistical graph showing the level of cell apoptosis after JAZF1 knockdown, knockout and overexpression detected by flow cytometry; Figure 17 (B) is a statistical graph showing the cell status after JAZF1 knockdown, knockout and overexpression detected by CCK8.

[0055] Figure 18 (A) shows the expression levels of BAX, BCL2, IGFBP1 and PRL after overexpression of JAZF1 detected by qRT-PCR; Figure 18 (B) shows the statistical graph of the protein expression levels of BCL2, cyt c and IGFBP1 after overexpression of JAZF1 detected by Western blot.

[0056] Figure 19 (A) is a graph showing the protein expression levels of BCL2, cyt c, and IGFBP1 after overexpression of JAZF1 detected by Western blot; Figure 19 (B) is a statistical graph showing the protein expression levels of BAX and cleaved-caspase3 after overexpression of JAZF1 detected by Western blot.

[0057] FIG20 is an expression graph and statistical graph showing the invasion ability of decidualized hESCs to HTR-8 / SVneo cells after JAZF1 knockdown.

[0058] FIG21 is an expression graph and statistical graph showing the invasion ability of decidualized hESCs to HTR-8 / SVneo cells after overexpression of JAZF1.

[0059] Figure 22 shows the transcription levels of BAX (left) and BCL2 (right) in RSA and control groups analyzed by scRNA-seq.

[0060] FIG23 shows the pathways enriched in decidual stromal cell subpopulation 1 (DS1), decidual stromal cell subpopulation 2 (DS2), and decidual stromal cell subpopulation 3 (DS3) analyzed by GO.

[0061] FIG24 is a statistical graph showing the expression levels of apoptosis-related genes BAX and BCL2 in decidual tissue detected by qRT-PCR.

[0062] FIG25 is a graph showing the expression levels of apoptosis-related genes BCL2, BAX, cleaved-caspase3, and cyt c in decidual tissue detected by Western blot.

[0063] FIG26 is a statistical graph showing the expression levels of apoptosis-related genes BCL2, BAX, cleaved-caspase3, and cyt c in decidual tissue detected by Western blot.

[0064] Figure 27 (A) shows the expression levels of apoptosis-related genes BCL2, BAX, cleaved-caspase3, and cyt c in primary decidual stromal cells detected by Western blot; Figure 27 (B) shows the expression levels of apoptosis-related genes BCL2, BAX, cleaved-caspase3, and cyt c in primary decidual stromal cells detected by Western blot.

[0065] FIG28 shows the expression levels of apoptosis-related genes BCL2, BAX, cleaved-caspase3, and cyt c in decidual tissues detected by immunohistochemistry.

[0066] FIG29 is a graph showing the overall apoptosis level of decidual tissue detected by TUNEL method.

[0067] Figure 30 (A) is the correlation analysis between BCL2 and JAZF1 in decidual tissue; Figure 30 (B) is the correlation analysis between cleaved-caspase3 and JAZF1 in decidual tissue; Figure 30 (C) is the correlation analysis between BAX and JAZF1 in decidual tissue; Figure 30 (D) is the correlation analysis between cyt c and JAZF1 in decidual tissue.

[0068] Figure 31 (A) is a graph showing the molecular diagnostic specificity analysis results of JAZF1 in the two groups of patients in Example 1; Figure 31 (B) is a Western blot analysis of JAZF1 expression in the normal group and the recurrent miscarriage group in four pairs of populations other than Example 1; Figure 31 (C) is a statistical graph showing the JAZF1 expression in the normal group and the recurrent miscarriage group in four pairs of populations other than Example 1; Figure 31 (D) is a graph showing the molecular diagnostic specificity analysis results of JAZF1 in four pairs of decidual tissue samples other than Example 1.

[0069] In the above figures, *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. DETAILED DESCRIPTION

[0070] The present invention will be further described in detail below with reference to specific examples. The following examples are not intended to limit the present invention but are merely intended to illustrate the present invention. The experimental methods used in the following examples are generally based on conventional conditions unless otherwise specified. The materials and reagents used in the following examples are all commercially available unless otherwise specified.

[0071] In the present invention, siRNA is a small interfering RNA that interferes with the expression of JAZF1 gene.

[0072] Example 1 Expression and localization of JAZF1 in decidual tissue of recurrent spontaneous abortion

[0073] (I) Using a 10× single-cell RNA sequencing (scRNA-seq) dataset, including decidual cells from six RSA and five gestationally matched normal abortions, all at 6-8 weeks of gestation, we found that JAZF1 was significantly downregulated in all decidual stromal cells in the RSA group (Figures 1-2).

[0074] (2) To further validate our scRNA-seq results, qRT-PCR and Western blotting were used to detect the expression of JAZF1 in decidual tissues of patients with recurrent miscarriage and elective abortion, as well as in primary decidual stromal cells extracted.

[0075] Experimental steps:

[0076] 1. Real-time quantitative PCR (RT-qPCR)

[0077] (1) RNA extraction from decidual tissue

[0078] 1) Pre-cool isopropanol, 75% ethanol, and centrifuge.

[0079] 2) Weigh 30 mg of decidual tissue in a mortar and grind into a fine powder with liquid nitrogen. Use a spoon to transfer to a sterile, enzyme-free 1.5 mL EP tube, add 1 mL of Trizol reagent, vortex, and let stand at room temperature for 5 min.

[0080] 3) Add 0.2 mL of chloroform, mix well, and let stand at room temperature for 5 minutes to allow the mixture to separate naturally;

[0081] 4) Centrifuge (centrifuge parameters: speed 12000g / min, temperature 4°C, time 15min). After centrifugation, the sample will separate into three layers. Pipette the upper aqueous phase into another sterile, enzyme-free 1.5mL EP tube.

[0082] 5) Add an equal volume of pre-chilled isopropanol to the aqueous phase, mix well, and let stand on ice for 10 minutes;

[0083] 6) Centrifuge. After centrifugation, a white precipitate will be seen at the bottom of the EP tube. Discard the supernatant.

[0084] 7) Add 1 mL of 75% ethanol to the EP tube to allow the precipitate to float in the 75% ethanol.

[0085] 8) Centrifuge (centrifuge parameters: speed 7500 rpm / min, temperature 4°C, time 12 min), discard the supernatant and repeat steps 7 and 8 once;

[0086] 9) Pour off the supernatant and let it stand at room temperature until the sediment at the bottom turns from white to transparent, which means it is dry enough.

[0087] 10) Add an appropriate volume of DEPC water according to the size of the precipitate to dissolve the RNA;

[0088] 11) Heat the RNA in a 37°C metal bath to promote RNA dissolution;

[0089] 12) Detect RNA samples with an A260 / A280 ratio between 1.8 and 2.0 using a Nanodrop 2000 spectrophotometer, record the RNA concentration, and proceed to the next reverse transcription experiment.

[0090] (2) Reverse transcription to synthesize cDNA (the following process is all performed on ice)

[0091] ① Step 1: Removal of genomic DNA (10 μL reaction system)

[0092] Table 1.

[0093] After mixing, incubate at 42°C for 2 min and store at 4°C or proceed to the next step.

[0094] ②Step 2: Reverse transcription (20 μL reaction system)

[0095] Table 2.

[0096] After mixing, incubate at 37°C for 15 minutes, 85°C for 5 seconds, add 180 μL DEPC and dilute 10 times, and store at -80°C.

[0097] (3) Real-time quantitative PCR (qRT-PCR)

[0098] ①Using TaKaRa TB Premix Ex Taq TM (10 μL reaction system);

[0099] Table 3.

[0100] ② Reaction conditions: 95°C for 30 seconds; (95°C for 5 seconds, 60°C for 30 seconds), 40 cycles. After amplification, obtain the corresponding CT value.

[0101] ③β-actin as an internal reference gene, 2 -△△CT Analyze the data.

[0102] The primers used in this study were synthesized by Guangzhou Funeng Company or Shanghai Jierui Company. The sequences are shown in the table below:

[0103] Table 4.

[0104] 2. Protein extraction and concentration determination

[0105] (1) Total protein extraction of decidual tissue

[0106] ① One day before the experiment, sterilize the experimental equipment at high temperature and pre-cool the centrifuge to maintain it at 4°C;

[0107] ② Prepare cell lysis buffer, protease inhibitor (PIC), and phosphatase inhibitor (PHI) in a volume ratio of 100:1:1 in advance. Mix the three thoroughly and place on ice.

[0108] ③ Weigh 35 mg of decidual tissue and place it in a grinding mortar. Add liquid nitrogen and grind it into a fine powder. Use a spoon to transfer it to an EP tube. Add 350 μL of the mixed lysis buffer and vortex to mix thoroughly.

[0109] ④ Place on ice and vortex once every 10 minutes for 3 times;

[0110] ⑤ After 30 minutes, centrifuge (centrifuge parameters: speed 14000 rpm / min, temperature 4°C, time 30 minutes), extract the supernatant and place it in another enzyme-free and sterile 1.5 mL EP tube. During the process, be careful to avoid sucking up the sediment at the bottom.

[0111] (2) Protein concentration determination by BCA method

[0112] The protein concentration of the sample to be tested was determined according to the operating instructions of the BCA protein quantification kit (purchased from ThermoFisher Scientific, cat. no. 23227);

[0113] (3) Protein packaging and storage

[0114] ① Calculate the required sample volume and add 1 / 3 volume of 4× sample buffer and mix thoroughly;

[0115] ② Place in a 100℃ metal bath for 10 min, shake thoroughly to mix, centrifuge and store at -80℃.

[0116] (4) SDS-PAGE gel preparation

[0117] The concentration of the stacking gel used in this example is 6%.

[0118] (5) Electrophoresis: Perform protein electrophoresis at room temperature at a constant current of 24 mA / plate. Stop electrophoresis when bromophenol blue reaches the bottom of the gel.

[0119] (6) Transfer: Electrotransfer instrument (constant voltage 100 V), the entire process is carried out at 4°C. Methanol is used to activate the PVDF membrane for 30 seconds, followed by shaking with double-distilled water for 3 minutes. The PVDF membrane and electrophoresis gel are then transferred to 1× transfer buffer and equilibrated for 10 minutes. The following splint is made: negative electrode - 2 sheets of filter paper - electrophoresis gel - PVDF membrane - 3 sheets of filter paper - positive electrode.

[0120] (7) Blocking: After transfer, place the PVDF membrane in the blocking solution and shake slowly, then incubate at room temperature for 1 hour.

[0121] (8) Primary Antibody Incubation: Rinse the remaining blocking solution with PBS, add the diluted primary antibody, shake slowly on a rocking platform, and incubate overnight at 4°C. The primary antibody dilution ratio is shown in Table 5 below.

[0122] Table 5.

[0123] (9) Membrane washing: Wash the PVDF membrane with PBS for 10 min × 3 times.

[0124] (10) Secondary antibody incubation: Add the diluted secondary antibody, place on a shaker and shake slowly, and incubate at room temperature for 1 hour.

[0125] (11) Membrane washing: Wash the PVDF membrane with PBS for 10 min × 3 times.

[0126] (12) Develop and take photos.

[0127] (13) Result processing: Western blot protein bands were quantitatively analyzed using ImageJ software and normalized using the expression level of the internal reference gene β-actin.

[0128] 3. Extraction of primary uterine decidual stromal cells

[0129] ① Wash the decidual tissue with sterile PBS solution 3-4 times, and then cut the decidual tissue into paste;

[0130] ② Transfer the decidual tissue to a 50 mL centrifuge tube and add digestion solution at a tissue volume:digestion solution volume ratio of 1:1. Place in a 37°C water bath for 1.5 hours, shaking and mixing every 20 minutes.

[0131] ③ Add an equal volume of 2% complete medium to terminate digestion, filter (100 μm), and filter (40 μm);

[0132] ④ Centrifuge (centrifuge parameters: speed 800 rpm / min, time 5 min), and remove the supernatant;

[0133] ⑤ Add 4 mL of red blood cell lysis buffer and allow to stand at room temperature for 10 minutes;

[0134] ⑥ Centrifuge (800 rpm / min, 5 min), remove the supernatant, add 10% complete medium to resuspend the cells, take a portion of the cells and inoculate them into a 4-well plate for immunofluorescence detection of the purity of primary uterine decidual stromal cells; the remaining cells were inoculated into a 10 cm culture dish and incubated in a 5% CO2, 37°C cell incubator overnight;

[0135] ⑦ After culturing for 24 hours, collect the cells in the 10 cm culture dish, add Trizol, and proceed to the next experiment.

[0136] Experimental results:

[0137] qRT-PCR (Figure 3, A) and Western blot (Figure 3, B, C) results indicated that JAZF1 mRNA and protein levels were significantly downregulated in RSA decidua tissue. Consistent with this, as shown in Figure 4 (A) and Figure 4 (B)-(C), JAZF1 mRNA and protein levels in primary decidual stromal cells isolated from RSA decidua were lower than those in the normal control group.

[0138] (3) Immunohistochemistry and immunofluorescence were used to detect the localization and relative expression level of JAZF1 in decidual tissue.

[0139] 1. Immunohistochemistry

[0140] 1) Sectioning: Paraffin sections of decidual tissue were serially sliced ​​to a thickness of 4 μm and developed in 42°C warm water.

[0141] 2) Slice baking: Decidual tissue slices were placed in a 65°C constant temperature electric slice baking machine and baked for 30 minutes;

[0142] 3) Dewaxing: Dewaxing the decidual tissue sections in xylene for 10 min*3 times, anhydrous ethanol for 10 min*2 times, 95% ethanol for 5 min*2 times, 85% ethanol for 5 min*2 times, 75% ethanol for 5 min*2 times, and then washed with running water;

[0143] 4) Antigen retrieval: Place the slide in the retrieval solution and heat in a pressure cooker at 1600W until the valve opens. Then, reduce the pressure to 900W and continue the retrieval for 15 minutes. Remove the retrieval box and let it cool.

[0144] 5) Soak and rinse with PBS to remove residual antigen retrieval solution;

[0145] 6) Place the slides in 3% H2O2 solution in the dark at room temperature for 10 minutes, and then wash with PBST for 5 minutes × 3 times;

[0146] 7) Drain the liquid, add 5% BSA blocking solution, and incubate at room temperature for 60 minutes;

[0147] 8) Remove the blocking solution, add the primary antibody dropwise (enough to completely cover the tissue), and incubate at 4°C overnight.

[0148] 9) Wash with PBST for 5 min × 3 times;

[0149] 10) Drain the liquid, add secondary antibody, incubate at room temperature for 60 minutes, and wash with PBST for 5 minutes × 3 times;

[0150] 11) Drain the liquid, add DAB colorimetric solution, and terminate the reaction in double-distilled water;

[0151] 12) Re-staining and re-blueing: Allow hematoxylin to act for 1 minute, and then stop the color development with tap water to avoid the nucleus from being too dark.

[0152] 13) Soak the slides in 75% ethanol for 3 minutes each, 85% ethanol for 3 minutes each, 95% ethanol for 3 minutes each, anhydrous ethanol for 3 minutes each, and xylene for 3 minutes each.

[0153] 14) Add neutral resin to seal the slide and place in a fume hood to dry;

[0154] 15) Immunohistochemical Image Analysis: The sections were photographed by another person, and five 400× fields of view were randomly selected for quantitative analysis using the IHC Profiler plug-in in ImageJ software. Negative, weakly positive, positive, and strongly positive were assigned scores of 1, 2, 3, and 4, respectively. The average of the five fields of view was calculated.

[0155] 2. Immunofluorescence detection experimental steps:

[0156] 1)-10) are consistent with the immunohistochemistry technique steps;

[0157] 11) Drain the liquid and gently add 1 μg / ml nuclear dye diamidinophenylindole (DAPI). Stain for 10 minutes at room temperature and wash with 1× PBST for 5 minutes.

[0158] 12) Use a pipette to draw up 50 μl of mounting medium to prevent fluorescence quenching and drop it onto the tissue on the slide. (If the tissue block is large, add more mounting medium as excessive amounts can easily create bubbles and affect the mounting effect.) Store the mounted slide at 4°C in the dark and photograph it under a fluorescence microscope as soon as possible.

[0159] Experimental Results: The immunohistochemistry results are shown in Figure 5 (A)-(B), and the immunofluorescence results are shown in Figure 6. It can be seen that JAZF1 is widely expressed in normal artificial abortion and RSA decidual tissues, mainly localized in the cell nucleus. The expression of JAZF1 in the cytoplasm and nucleus of RSA decidual stromal cells is lower than that in the gestational age-matched normal control group. These results indicate that JAZF1 expression is significantly downregulated in the decidual stromal cells of RSA patients.

[0160] (IV) To explore the potential function of JAZF1 in decidualization, we induced decidualization of human endometrial stromal cells (HESCs) in vitro and detected changes in JAZF1 mRNA and protein levels as well as the expression of decidualization-related markers IGFBP1, PRL, and FOXO1.

[0161] The in vitro induction of decidualization of human endometrial stromal cell lines specifically includes the following steps: when the cell density reaches 50% under a light microscope, decidualization is induced in vitro: control group: 2% complete culture medium; experimental group: decidualization induction medium (2% complete culture medium: 4mM medroxyprogesterone acetate solution: cyclic adenosine monophosphate solution volume ratio of 1000:1:10), 2 ml / well, cell morphological changes are observed under a light microscope every day, decidualization induction medium is replaced every 2 days, and cells are collected 6 days after decidualization for the next experiment.

[0162] Experimental results:

[0163] The results of western blot are shown in Figure 7 (A)-(B), and the results of immunofluorescence are shown in Figure 8. The experimental results showed that with the progress of decidualization, the expression of decidualization-related markers IGFBP1, PRL and FOXO1 increased, and the expression of JAZF1 also gradually increased.

[0164] (V) To validate the results of the above in vitro experiments, we used immunohistochemistry to examine JAZF1 expression in human endometrium during the proliferative and early secretory phases. The immunohistochemistry results for human endometrium during the proliferative and early secretory phases are shown in Figures 9 and 10 (A). These results suggest that JAZF1 protein abundance is higher in the early secretory phase of the endometrium than in the proliferative phase, particularly in stromal cells.

[0165] By accessing single-cell sequencing data from endometrial tissue in public databases, we analyzed the expression of JAZF1 in endometrial tissue and stromal cells at different stages. The scRNA-seq data from the endometrial public dataset are shown in Figure 10 (B). The results show that compared with the proliferative stage, JAZF1 expression is upregulated in the early secretory endometrium and also in stromal cells.

[0166] Immunohistochemical results showed that JAZF1 expression was downregulated in both the proliferative and early secretory endometrium of RSA patients. These results suggest that JAZF1 is a potential regulator of the establishment and development of decidualization.

[0167] Example 2 Effects of JAZF1 knockout on hESCs survival and decidualization

[0168] (I) Effective knockout and overexpression of JAZF1 in HESCs

[0169] To investigate the role of JAZF1 in endometrial stromal cells, we used siRNA knockdown (siJAZF1), CRISPR / Cas9 knockout (KO-JAZF1), and lentiviral overexpression of JAZF1 (OE-JAZF1). After 48 hours of culture, cells were harvested to assess the efficiency of JAZF1 knockdown, knockout, and overexpression. We then performed Sanger sequencing on DNA fragments obtained from PCR-generated KO stable transfectants with effective knockout efficiency to confirm whether the sgRNA targeted the JAZF1 coding region.

[0170] 1. siRNA transfection:

[0171] JAZF1-siRNA was designed and synthesized by Genemax, a Chinese company. Transfection was performed using Lipofectamine RNA iMAX. The specific steps are as follows:

[0172] ① One day before transfection, seed the cells at an appropriate density in a 6-well plate to achieve a 40-50% fusion rate at the time of transfection, add complete medium and culture overnight.

[0173] ② 60 minutes before transfection, remove the old culture medium and add 1.5 mL of fresh culture medium without antibiotics.

[0174] ③ For each transfected well, prepare a mixture of siRNA and Lipofectamine RNAiMAX.

[0175] 1) Add 100 pmole (5 μL) of siRNA to 250 μL of serum-free growth medium and mix well.

[0176] 2) Lipofectamine RNA iMAX should be mixed before use. Then, dilute it by adding 5 μL of Lipofectamine RNA iMAX to 250 μL of growth medium and incubate at room temperature for 5 minutes.

[0177] 3) Mix the diluted siRNA and Lipofectamine RNA iMAX and incubate at room temperature for 20 minutes.

[0178] ④Add the mixture to the cells to a final volume of 2 mL per well and shake gently to mix.

[0179] ⑤Cultivate cells in a 37°C, 5% CO2 incubator for 6 hours.

[0180] ⑥ Replace the culture medium containing 10% serum and continue to culture the cells for 48-72 hours until the gene knockout experiment is performed.

[0181] The siRNA sequences used in this study are listed in the following table:

[0182] Table 6.

[0183] 2. Establishment of JAZF1 knockout cell lines

[0184] The JAZF1 KO cell line was established using CRISPR / Cas9 technology. The specific steps are as follows:

[0185] (1) Search the coding region sequence of JAZF1 at NCBI.

[0186] (2) Copy the sequence into https: / / portals.broadinstitute.org / gpp / public / and design sgRNA.

[0187] (3) Verify the sgRNA and select the sequence with 100% specificity for synthesis.

[0188] (4) Lentiviral vector enzyme digestion system:

[0189] Table 7.

[0190] 5 μg of lentiviral CRISPR plasmid was digested and dephosphorylated with BsmBI and reacted at 37°C for 30 min.

[0191] (5) The enzyme-digested plasmid was subjected to agarose electrophoresis and the enzyme-digested plasmid was recovered using a gel recovery kit. The specific gel recovery steps are as described above.

[0192] (6) Phosphorylation and annealing sgRNA system configuration:

[0193] Table 8.

[0194] (7) Annealing PCR system:

[0195] Table 9.

[0196] (8) Dilute the primers that have been annealed in step (7) into sterile water at a ratio of 1:100.

[0197] (9) Annealed sgRNA and enzyme-cut plasmid vector connection system:

[0198] Table 10.

[0199] 16℃, overnight.

[0200] (10) Transformation

[0201] 1) Thaw a tube of DH5-alpha competent E. coli cells on ice until the last ice crystal disappears. Gently pipette 50 μL of cells into a transformation tube on ice.

[0202] 2) Add 5 μL of the plasmid DNA ligated the day before to the cell mixture and mix.

[0203] 3) Place the mixture on ice for 30 minutes. Do not vortex.

[0204] 4) Heat at 42°C for 30 seconds to activate competent cells. Place on ice for 3 minutes.

[0205] 5) Pipette 950 μL of room temperature LB liquid medium into the competent cells in 4).

[0206] 6) Incubate at 37°C for 60 minutes with vigorous shaking (250 rpm) or rotation.

[0207] 7) Before coating, centrifuge the bacterial solution from 6) at 3500 rpm for 5 minutes, remove 800 μL of the supernatant, and mix the remaining bacterial solution with a pipette tip.

[0208] 8) Spread 100 μL of the bacterial dilution onto a selection plate and incubate at 37°C overnight.

[0209] 9) Pick a single bacterium with a larger area and place it in the culture medium. Add 1000× ampicillin.

[0210] 10) Take 4 mL of bacterial culture for small extraction and sequence the plasmid to confirm whether the sequence inserted in the plasmid is the designed sgRNA.

[0211] (11) The three bacterial cultures with correct sequencing sequences were placed into 100 mL of LB liquid culture medium, 100 μL of 1000× ampicillin was added, and the culture medium was placed in a constant temperature shaker at 37°C and 200 rpm for overnight shaking.

[0212] (12) Take 500 μL of bacterial solution, add 500 μL of glycerol, mix, and store at -80°C.

[0213] (13) HEK 293T cells were used for lentiviral packaging and transfection of HESCs as follows (10 cm culture dish):

[0214] 1) On day 1, 2.5×10 cells were seeded in each well in 10 mL of culture medium. 6 HEK 293T cells (AM) or 3 × 10 6 HEK 293T cells (PM).

[0215] 2) On the morning of day 2, prepare a mixture of the three plasmids in a clean 1.5 mL EP tube:

[0216] Table 11.

[0217] The mixture was vortexed and incubated for 10 min, and then added dropwise to the culture medium of HEK 293T cells.

[0218] 3) After 6-8 hours, change the medium to 10% complete culture medium.

[0219] 4) One day before collecting the virus, plate HESCs at a number of 1.5×10 5 .

[0220] 5) Filter the viral supernatant with a 0.44 μm filter, then add the supernatant from a 10 cm dish to one well of the hESCs in a 6-well plate. After 24 hours, change the medium to 10% complete culture medium.

[0221] (17) 72 hours after transfection of the target cells, 1.3 mg / mL Neomycin was used for 72 hours of drug screening.

[0222] (18) After the drug screening, the total JAZF1-KO cells were digested, diluted, and seeded into a 96-well plate at a density of 1 cell / well. The cells were collected to extract RNA and DNA.

[0223] (19) RNA was extracted to detect the JAZF1 knockout efficiency, DNA was extracted (specific steps are the same as above) and PCR amplification was performed (specific steps are the same as above), and the amplified products were subjected to Sanger sequencing to confirm the plasmid genotype.

[0224] (20) After the genotype is confirmed, the corresponding JAZF1-KO cell line can be amplified and the next step of the experiment can be carried out.

[0225] 3. DNA PCR

[0226] (1) Reaction system:

[0227] Table 12.

[0228] When amplifying products ≥ 10 kb in length, use primers at a final concentration of 0.2 μM.

[0229] (2) PCR amplification procedure:

[0230] Table 13.

[0231] (3) A total of 30 cycles of amplification were performed, and after completion, agarose gel electrophoresis was performed to identify whether the band was the target gene. After confirmation, the band was sent for Sanger sequencing.

[0232] The PCR primer sequences used in this study are as follows:

[0233] Table 14.

[0234] 4. Establishment of overexpression cell lines:

[0235] (1) Overexpression PCR primer design: Find the DNA coding region of the target gene on the NCBI website and open it with snapgene software.

[0236] (2) Select appropriate enzyme cutting sites: Select two enzyme cutting sites that are present on the plasmid vector but not in the coding region of the target gene. After designing, hand them over to the company for synthesis.

[0237] (3) Enzyme digestion of overexpression plasmid vector, the system is as follows:

[0238] Table 15.

[0239] (4) PCR amplify the complete CDS region of the target gene using the following system:

[0240] Table 16.

[0241] When amplifying products ≥ 10 kb in length, use primers at a final concentration of 0.2 μM.

[0242] (5) PCR amplification procedure:

[0243] Table 17.

[0244] (6) A total of 30 cycles of amplification were performed, and after completion, 1% agarose gel electrophoresis was performed to determine the molecular weight of the PCR product by comparing it with the molecular weight of the DNA marker to determine whether the DNA coding region of the target gene was completely PCR-encoded.

[0245] (7) After successful PCR, the PCR product is recovered by gel recovery.

[0246] (8) All the recovered gel products were subjected to enzymatic digestion at 37°C for 60 min using the following system:

[0247] Table 18.

[0248] (9) The enzyme digestion products were subjected to 1% agarose gel electrophoresis and the electrophoresis products were recovered from the gel.

[0249] (10) Ligate the enzyme-cut DNA fragments with the enzyme-cut plasmid vectors. The system is as follows:

[0250] Table 19.

[0251] Ligate overnight at 16°C. The volume ratio of the DNA fragment mass:molecular weight to the plasmid vector mass:molecular weight in the ligation system is 1:3, which can be used to calculate the required volumes of DNA fragment and double-distilled water.

[0252] (11) Convert the plate, the steps are the same as before.

[0253] (12) The steps of picking single clones, extracting plasmids, sequencing, extracting plasmids in medium quantity, packaging lentivirus and drug screening are the same as before.

[0254] (13) After the drug screening, a portion of the cells was taken to extract RNA, and the overexpression efficiency was detected by qRT-PCR.

[0255] The overexpression primer sequences used in this study are as follows:

[0256] Table 20.

[0257] Experimental results:

[0258] The qRT-PCR results of siRNA knockdown, CRISPR / Cas 9 knockout, and lentiviral overexpression of JAZF1 are shown in Figure 11 (A), and the Western blot results are shown in Figure 11 (B). It can be seen that compared with the control group, the mRNA and protein levels of JAZF1 in the siRNA and lentiviral treatment groups were significantly decreased, while the expression level of JAZF1 in the overexpression treatment group was significantly upregulated, confirming the effective knockdown, knockout, and overexpression efficiency.

[0259] Sanger sequencing was performed on the DNA fragments obtained after PCR in the stable KO strain with effective knockout efficiency to confirm whether the sgRNA targeted the coding region of JAZF1. The Sanger sequencing results are shown in Figure 12. The results show that the coding region of the DNA of the edited stable strain is missing one base, the stop codon is premature, and gene transcription is terminated prematurely, indicating that the stable strain is effective.

[0260] (II) Effects of JAZF1 knockdown on HESCs survival and decidualization

[0261] After HESCs were treated with siRNA and KO lentivirus, decidualization was induced in vitro with cyclic adenosine monophosphate (cAMP) and medroxyprogesterone acetate (MPA) for 6 days. The induction medium was replaced every two days, and the expression of cell apoptosis and decidualization-related indicators was detected by qRT-PCR and Western blotting.

[0262] Experimental results:

[0263] The qRT-PCR results, shown in Figure 13, indicate that knockdown or ablation of JAZF1 upregulated the expression of the pro-apoptotic molecule BAX, while downregulated the anti-apoptotic molecule BCL2. Western blot results, shown in Figures 14 and 15, also demonstrate that knockdown or ablation of JAZF1 significantly upregulated the protein levels of the pro-apoptotic molecules BAX, cyt c, and cleaved-caspase 3, while significantly downregulated the anti-apoptotic molecule BCL2.

[0264] (III) Flow cytometry was used to detect the anti-apoptotic effect of JAZF1 on decidualized HESCs, and CCK8 was used to detect the cell proliferation status.

[0265] Experimental steps:

[0266] 1. Flow cytometry combined with Annexin V / PI to detect cell apoptosis

[0267] (1) Induce cell apoptosis according to experimental requirements. Untreated cell samples serve as negative controls. When performing flow cytometry, cells from the experimental groups should be stained with Annexin V-FITC and PI for compensation.

[0268] (2) Collect 1×10 5 -5×10 5 Digest the cells with EDTA-free trypsin, collect the cells after digestion, centrifuge at 1000 rpm and 4°C for 5 min, and discard the supernatant.

[0269] (3) Washing cells: Wash the cells twice with pre-cooled PBS, centrifuging at 1000 rpm and 4°C for 5 min each time, and discard the supernatant.

[0270] (4) Cell resuspension: Add 100 μL of 1× Binding Buffer and gently pipette to form a single-cell suspension.

[0271] (5) Cell staining: Add 5 μL Annexin V-FITC and 5 μL PI Staining Solution and mix well. Incubate at room temperature for 10 min in the dark. Add 400 μL 1× Binding Buffer and mix well. Detect by flow cytometry.

[0272] (6) Flow cytometric analysis: The excitation wavelength of the flow cytometer is 488 nm; the green fluorescence of FITC is detected in the FL1 channel; the red fluorescence of PI is detected in the FL2 or FL3 channel. In the present invention, FL3 is used, and 10,000 events are collected for each sample. Data analysis is performed using software such as FlowJo, with FL1 as the horizontal axis and FL3 as the vertical axis. The positive and negative boundaries of the two fluorescence parameters are determined based on the FITC and PI fluorescence values, and a cross gate is drawn. In a typical experiment, cells can be divided into three subpopulations: live cells are double negative (Annexin V-FITC ﹣ / PI ﹣ ); Early apoptotic cells are Annexin V-FITC single positive (Annexin V-FITC ﹢ / PI ﹣ ); Late apoptotic cells are double positive for Annexin V-FITC and PI (Annexin V-FITC ﹢ / PI ﹢ ).

[0273] 2. Cell proliferation activity detection

[0274] (1) Preparation of standard curve

[0275] 1) Set up four concentration gradients: 1000, 2500, 5000, and 10,000 cells / well. Count cells after passage and dilute with culture medium to the indicated concentrations. Set up five replicate wells per group.

[0276] 2) After 4 hours of cell attachment, add 10 μL of CCK-8 reagent and incubate for 2, 3, and 4 hours. Measure the OD value. Incubate for 3 hours, with cell number as the horizontal axis and OD value as the vertical axis.

[0277] (2) Detection of cell proliferation activity

[0278] 1) Add 1*10 4 Add 100 μL of sterile PBS to the edge of the well.

[0279] 2) After incubation in the incubator for 24 hours, add 10 μL of CCK8 to each well and mix thoroughly by pipetting. Keep the well protected from light.

[0280] 3) After incubation in the incubator for 4 hours, measure the absorbance of each well at a wavelength of 450 nm using an absorbance microplate reader.

[0281] 4) Data statistics: The average value of 5 replicate wells in each group was taken and compared among the groups.

[0282] Experimental results:

[0283] Flow cytometry results, shown in Figures 16 and 17 (A), indicate that JAZF1 deficiency induces apoptosis. CCK8 results (Figure 17 (B)) indicate that knockdown and ablation of JAZF1 significantly downregulate the proliferative capacity of stromal cells that induce decidualization. Furthermore, JAZF1 deficiency upregulates the mRNA and protein expression levels of PRL and IGFBP-1, resulting in decidualization defects.

[0284] (IV) HESCs were treated with a lentivirus overexpressing JAZF1 and then induced to decidualize in vitro with cAMP and MPA for 6 days. Cell apoptosis and the expression of decidualization-related markers were assessed by qRT-PCR and Western blotting. Flow cytometry was used to measure apoptosis, and CCK8 was used to assess cell proliferation. Specific experimental procedures were the same as above.

[0285] qRT-PCR results, shown in Figure 18 (A), demonstrate that overexpression of JAZF1 downregulates the levels of the apoptotic molecule BAX, upregulates the anti-apoptotic molecule BCL2, and simultaneously downregulates the levels of decidualized IGFBP1 and PRL. Western blot results, shown in Figure 18 (B) and Figure 19 (A)-(B), indicate that overexpression of JAZF1 only downregulates the levels of IGFBP1 and cyt c and upregulates BCL2, but does not alter the levels of BAX and cleaved-caspase 3. Flow cytometry and CCK8 assays demonstrate that overexpression of JAZF1 downregulates apoptosis in HESCs (Figure 17 (A)) and upregulates cell proliferation (Figure 17 (B)).

[0286] Taken together, these results demonstrate that JAZF1 can prevent excessive apoptosis and decidualization defects of HESCs during decidualization.

[0287] Example 3 Effects of JAZF1 knockdown or overexpression in HESCs on the invasion ability of HTR-8 / SVneo cells

[0288] Studies have shown that disordered decidual reaction or excessive IGFBP1 in decidual cells are associated with miscarriage, fetal growth retardation or spontaneous premature birth. The present invention further evaluated the effect of JAZF1 knockout HESCs on trophoblast cell invasion. First, HESCs were treated with siRNA for 6 hours to induce decidualization or the OE-JAZF1 stable transgenic line was directly induced. After 6 days of treatment, the supernatant was taken under the chamber and an appropriate number of HTR-8 / SVneo cells were co-cultured on top of the chamber matrix gel. Transwell experiments showed that HESCs after JAZF1 knockout inhibited the invasion of HTR-8 / SVneo cells (Figure 20), while overexpression of JAZF1 promoted its invasion (Figure 21), proving that the loss of JAZF1 has an adverse effect on the function of decidual stromal cells.

[0289] Example 4 Apoptosis level of decidual stromal cells in recurrent miscarriage

[0290] (1) 10× single-cell sequencing analysis of apoptosis of decidual stromal cells

[0291] Given that JAZF1 downregulation observed during in vitro decidualization has a pro-apoptotic effect, we further evaluated the apoptosis level in decidual tissues and primary DSCs from RSA and control groups. Our previous scRNA-seq analysis of DSCs showed that the pro-apoptotic gene BAX was significantly increased in DS in the RSA group, but BCL2 did not change significantly (Figure 22). In addition, GO enrichment analysis of upregulated genes in RSA also showed that apoptosis and cell death pathways were significantly activated in DS1, DS2, and DS3 compared with the control group (Figure 23).

[0292] (2) Apoptosis of decidual stromal cells in recurrent miscarriage

[0293] To verify the results of single-cell sequencing, qRT-PCR, western blot, and immunohistochemistry were used to detect the expression levels of apoptosis-related genes BAX, cyt c, cleaved-caspase 3, and BCL2 in decidual tissues and primary decidual stromal cells.

[0294] Experimental results:

[0295] qRT-PCR analysis of apoptosis-related gene expression levels in decidual tissue is shown in Figure 24 , and Western blot analysis of apoptosis-related gene expression levels in decidual tissue is shown in Figures 25 and 26 . The results show that the pro-apoptotic genes BAX, cyt c, and cleaved-caspase 3 are significantly upregulated in RSA decidual tissue, while the anti-apoptotic gene BCL2 is downregulated. Furthermore, the same expression pattern was observed in primary decidual stromal cells isolated from RSA decidua (Figures 27, AB). These results were further confirmed by immunohistochemistry (Figure 28).

[0296] (3) TUNEL staining was used to detect the overall apoptosis level of decidual tissue.

[0297] Experimental steps:

[0298] 1. TUNEL assay:

[0299] (1) Sample pretreatment: paraffin-embedded tissue sections.

[0300] (2) Positive treatment

[0301] After sample permeabilization, positive controls can be prepared by treating the sample with DNase I.

[0302] 1) Dilute 10× DNase I Buffer to 1× DNase I Buffer at a ratio of 1:10 with double-distilled water. Prepare 200 μL of 1× DNase I Buffer for each sample.

[0303] 2) Add 100 μL of 1× DNase I Buffer to the permeabilized sample and equilibrate at room temperature for 5 minutes.

[0304] 3) Dilute DNase I (2 U / μL) with 1× DNase I Buffer to a final concentration of 20 U / mL.

[0305] 4) Gently remove excess liquid, add 100 μL of 20 U / mL DNase I working solution, and incubate at room temperature for 10 minutes.

[0306] 5) Gently aspirate any excess liquid and rinse the slide / slide thoroughly in a staining jar filled with 1x PBS 2-3 times. A separate staining jar must be used for the positive control slide. Residual DNase I on the positive control slide / slide may cause false positive signals in the experimental group.

[0307] (3) Labeling and detection

[0308] 1) Dilute 5× Equilibration Buffer to 1× Equilibration Buffer at a ratio of 1:5 with double-distilled water.

[0309] 2) Add 100 μL of 1× Equilibration Buffer to completely cover the sample area to be tested and equilibrate at room temperature for 10-30 minutes.

[0310] 3) During the equilibration period, prepare the labeling solution according to the table below in the dark.

[0311] Table 21.

[0312] For areas less than 5cm 2 For a 50 μL reaction, multiply 50 μL by the number of experimental and positive control reactions to determine the total volume of TdT incubation buffer required. For samples with larger surface areas, the reagent volume can be increased proportionally.

[0313] 4) After equilibration, remove the 1× Equilibration Buffer with absorbent paper, and then add 50 μL of TdT incubation buffer to the sample.

[0314] 5) Cut the parafilm to the same size as the tissue or slide and gently cover the sample to ensure even distribution of the reagent. Place the slide in a humidified chamber and incubate at 37°C for 60 minutes. Wrap the chamber with aluminum foil to protect it from light.

[0315] 6) Wash twice with fresh 1× PBS solution, incubating at room temperature for 5 minutes each time. After washing with 1× PBS, the sample can be washed three times with PBS containing 0.1% Triton X-100 and 5 mg / mL BSA, each for 5 minutes.

[0316] 7) Counterstain the sample with 2 μg / mL DAPI solution in the dark and leave it at room temperature for 5 minutes.

[0317] 8) Wash the samples by immersing the slides in 1× PBS solution for three times, each time at room temperature for 5 minutes.

[0318] 9) Add 100 μL of 20% glycerol prepared in 1× PBS to the sample area to keep the sample moist.

[0319] 10) Immediately analyze the sample under a fluorescence microscope, using a standard fluorescence filter set at 620 ± 20 nm for BrightRed red fluorescence and 460 nm for DAPI blue fluorescence. If necessary, the sample can be mounted on a slide and stored overnight at 4°C in the dark. DAPI stains both apoptotic and non-apoptotic cells blue. Red fluorescence, produced by BrightRed incorporation, is only observed in the nuclei of apoptotic cells.

[0320] Experimental results:

[0321] The results of TUNEL staining are shown in FIG29 , which show that the fluorescence intensity of the decidual tissue in the RSA group was higher than that in the control group, indicating that the apoptosis level of the decidual tissue in the RSA group was higher.

[0322] (IV) Analyze the relationship between JAZF1 and the expression levels of apoptosis-related molecules.

[0323] Figure 30 (A) shows the correlation analysis between BCL2 and JAZF1 in decidual tissue, Figure 30 (B) shows the correlation analysis between cleaved-caspase 3 and JAZF1 in decidual tissue, Figure 30 (C) shows the correlation analysis between BAX and JAZF1 in decidual tissue, and Figure 30 (D) shows the correlation analysis between cyt c and JAZF1 in decidual tissue. We noted that BCL2 expression was positively correlated with JAZF1 expression levels, while an opposite trend was observed for cleaved-caspase 3. No correlation was observed between BAX and cyt c and JAZF1.

[0324] Example 5

[0325] The ROC curve was used to establish a JAZF1 prediction model for recurrent spontaneous abortion in the two groups of patients in Example 1, and the AUC value, sensitivity, specificity, positive detection rate, negative detection rate and Youden index of the prediction method were calculated. The results are shown in Table 22 and A in Figure 31.

[0326] Table 22 Molecular diagnostic specificity analysis of JAZF1 in the original 10 pairs of decidual tissue samples

[0327] The results showed that JAZF1 expression could be used to predict recurrent miscarriage, with an AUC value of 0.79; a high sensitivity of 0.90; a medium specificity of 0.60; an optimal cutoff value of 0.3654; a positive predictive value of 0.90; a negative predictive value of 0.60; and a Youden index of 0.50.

[0328] At the same time, Table 23 and Figure 31B-Figure 31C show that in the 4 pairs of test populations other than Example 1, the JAZF1 expression values ​​were significantly different in the normal group and the recurrent spontaneous abortion group (p<0.05). The disease was diagnosed in the 4 pairs of patients using the optimal cutoff value, with a true positive rate of 0.75, a false positive rate of 0, a true negative rate of 1.00, and a false negative rate of 0.25, indicating a good diagnostic effect.

[0329] Table 23 Detection rates of 4 pairs of decidual tissue samples other than Example 1

[0330] We further used the ROC curve to establish a model for predicting recurrent spontaneous abortion based on JAZF1 expression in the four tissue pairs in Example 5, and calculated the AUC value, sensitivity, specificity and Youden index of the prediction method. The results are shown in Table 24 and D in Figure 31.

[0331] Table 24 Molecular diagnostic specificity analysis of JAZF1 in 4 pairs of decidual tissue samples other than Example 1

[0332] The results showed that JAZF1 expression can be used to predict recurrent miscarriage, with an AUC value of 0.94; good sensitivity of 0.75; high specificity of 1.00; and a Youden index of 0.75.

Claims

1. Application of JAZF1 gene in the preparation of products for diagnosis or auxiliary diagnosis of abortion.

2. The use according to claim 1, characterized in that: The abortion is recurrent abortion.

3. The use according to claim 1, characterized in that: The diagnostic products include: products for diagnosing miscarriage using qRT-PCR, immunoassay, Western blot assay, immunohistochemistry assay, immunofluorescence, flow cytometry, and single-cell sequencing.

4. The use according to claim 1, characterized in that: The product is selected from one or more of a test kit, a gene chip, a protein chip, a preparation, a test kit quality control product, and a test kit standard product.

5. The use according to claim 1, characterized in that: The application steps are as follows: (1) Detecting the expression level of the JAZF1 gene in the sample to be tested; (2) comparing the expression level of the JAZF1 gene in the test sample with that in the control group; (3) Compared with the level in the control group, the expression of JAZF1 gene in the test sample is downregulated, indicating that the subject is a miscarriage patient, otherwise, the subject is not a miscarriage patient.

6. Use of a reagent for detecting the JAZF1 gene in the preparation of a diagnostic or auxiliary diagnostic product for abortion, characterized in that: The reagent detects the mRNA expression level or protein expression level of the JAZF1 gene.

7. A product for diagnosing or assisting in the diagnosis of miscarriage, characterized in that: The product includes a reagent for detecting the expression level of the JAZF1 gene in a sample to be tested.

8. The product according to claim 7, characterized in that The sample to be tested is selected from one or more of decidual tissue, endometrial tissue, and decidual stromal cells.

9. Use of a substance that enhances the content or activity of the JAZF1 gene in the preparation of a drug for treating or preventing miscarriage.

10. The use according to claim 9, characterized in that: The functions of the application are any one or more of the following: (1) Promote the proliferation of endometrial stromal cells; (2) inhibiting apoptosis of endometrial stromal cells; (3) Maintain normal decidualization of endometrial stromal cells.

Citation Information

Patent Citations

  • Gene chip for detecting mutation of 18 loci of susceptibility genes of type 2 diabetes

    CN101956017A

  • Sarcoma fusion gene and / or mutation joint detection primer group and kit

    CN112094915A

  • MiRNA marker for diagnosing early abortion and application thereof

    CN114438187A

  • Application of marker in preparation of prostate cancer diagnostic product

    CN115820861A

  • Molecular marker for recurrent abortion and diagnostic application

    CN116837105A